Resveratrol suppresses the epithelial-to-mesenchymal transition in PC-3 cells by down-regulating the PI3K/AKT signaling pathway

References

• Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA. 2012. Resveratrol: potential as anticancer agent. J Diet Suppl. 9:45–56. doi: 10.3109/19390211.2011.650842
   PubMedGoogle Scholar
• Baur JA. 2010. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech Ageing Dev. 131:261–269. doi: 10.1016/j.mad.2010.02.007
   PubMed Web of Science ®Google Scholar
• Bhavsar T, McCue P, Birbe R. 2013. Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol. 40:259–275. doi: 10.1053/j.seminoncol.2013.04.002
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, et al. 2011. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 13:317–323. doi: 10.1038/ncb2173
   PubMed Web of Science ®Google Scholar
• Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E, Llaurado M, Rigau M, Olivan M, Garcia M, et al. 2012. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol. 14:715–720. doi: 10.1007/s12094-012-0866-3
   PubMed Web of Science ®Google Scholar
• Franco-Chuaire ML, Magda Carolina SC, Chuaire-Noack L. 2013. Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin. 54:186–205.
   PubMed Web of Science ®Google Scholar
• Fulda S. 2010. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today. 15:757–765. doi: 10.1016/j.drudis.2010.07.005
   PubMed Web of Science ®Google Scholar
• Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA, Liu H, Garraway IP, Isaacs JS. 2012. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 287:37732–37744. doi: 10.1074/jbc.M112.389015
   PubMed Web of Science ®Google Scholar
• Knobloch J, Hag H, Jungck D, Urban K, Koch A. 2011. Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease. Basic Clin Pharmacol Toxicol. 109:138–143. doi: 10.1111/j.1742-7843.2011.00707.x
   PubMed Web of Science ®Google Scholar
• Kundu JK, Surh YJ. 2008. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 269:243–261. doi: 10.1016/j.canlet.2008.03.057
   PubMed Web of Science ®Google Scholar
• Li W, Ma J, Ma Q, Li B, Han L, Liu J, Xu Q, Duan W, Yu S, Wang F, et al. 2013. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway. Curr Med Chem. 20:4185–4194. doi: 10.2174/09298673113209990251
   PubMed Web of Science ®Google Scholar
• Lu T, Lin WJ, Izumi K, Wang X, Xu D, Fang LY, Li L, Jiang Q, Jin J, Chang C. 2012. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol. 26:1707–1715. doi: 10.1210/me.2012-1079
   PubMed Web of Science ®Google Scholar
• Pervaiz S, Holme AL. 2009. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal. 11:2851–2897. doi: 10.1089/ars.2008.2412
   PubMed Web of Science ®Google Scholar
• Pirola L, Frojdo S. 2008. Resveratrol: one molecule, many targets. IUBMB Life. 60:323–332. doi: 10.1002/iub.47
   PubMed Web of Science ®Google Scholar
• Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, Srivastava RK. 2011. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One. 6:e16530. doi: 10.1371/journal.pone.0016530
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. doi: 10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Snyder A, Tepper JE, Slovin SF. 2013. Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? Semin Oncol. 40:347–360. doi: 10.1053/j.seminoncol.2013.04.009
   PubMed Web of Science ®Google Scholar
• Sun C, Hu Y, Liu X, Wu T, Wang Y, He W, Wei W. 2006. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 165:9–19. doi: 10.1016/j.cancergencyto.2005.06.016
   PubMed Web of Science ®Google Scholar
• Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. 2001. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res. 61:589–593.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. 2009. Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. doi: 10.1016/j.cell.2009.11.007
   PubMed Web of Science ®Google Scholar
• Tombal B, Alcaraz A, James N, Valdagni R, Irani J. 2014. Can we improve the definition of high-risk, hormone naive, non-metastatic prostate cancer? BJU Int. 113:189–199. doi: 10.1111/bju.12469
   PubMed Web of Science ®Google Scholar
• Van der Kwast TH. 2014. Prognostic prostate tissue biomarkers of potential clinical use. Virchows Arch. 464:293–300. doi: 10.1007/s00428-014-1540-7
   PubMed Web of Science ®Google Scholar
• Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, et al. 2011. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 6:e19881. doi: 10.1371/journal.pone.0019881
   PubMed Web of Science ®Google Scholar
• Vergara D, Simeone P, Toraldo D, Del Boccio P, Vergaro V, Leporatti S, Pieragostino D, Tinelli A, De Domenico S, Alberti S, et al. 2012. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst. 8:1078–1087. doi: 10.1039/c2mb05486h
   PubMed Web of Science ®Google Scholar
• Vergara D, Valente CM, Tinelli A, Siciliano C, Lorusso V, Acierno R, Giovinazzo G, Santino A, Storelli C, Maffia M. 2011. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett. 310:1–8. doi: 10.1016/j.canlet.2011.04.009
   PubMed Web of Science ®Google Scholar
• Whitlock NC, Baek SJ. 2012. The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer. 64:493–502. doi: 10.1080/01635581.2012.667862
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Christofori G. 2010. Mechanisms of motility in metastasizing cells. Mol Cancer Res. 8:629–642. doi: 10.1158/1541-7786.MCR-10-0139
   PubMed Web of Science ®Google Scholar